AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Glutamine--fructose-6-phosphate aminotransferase [isomerizing] 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q06210

UPID:

GFPT1_HUMAN

Alternative names:

D-fructose-6-phosphate amidotransferase 1; Glutamine:fructose-6-phosphate amidotransferase 1; Hexosephosphate aminotransferase 1

Alternative UPACC:

Q06210; Q53QE6; Q9BXF8

Background:

Glutamine--fructose-6-phosphate aminotransferase [isomerizing] 1, also known as D-fructose-6-phosphate amidotransferase 1, plays a pivotal role in glucose metabolism by controlling the flux into the hexosamine pathway. This enzyme is crucial for the synthesis of N- and O-linked glycoproteins, impacting cellular communication and signaling.

Therapeutic significance:

The enzyme's involvement in congenital myasthenic syndrome 12, characterized by muscle weakness and neuromuscular junction dysfunction, highlights its therapeutic potential. Understanding its role could lead to targeted treatments for this syndrome, leveraging its response to acetylcholinesterase inhibitors.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.